• 1. Exchangeability of amino acid residues with similar physicochemical properties in coiled-coil interactions?
  Guiying Zhang,Maosheng Cheng,Yanni Li,Keliang Liu,Lifeng Cai Chem. Commun., 2013,49, 11086-11088
• 2. Fast synthesis of copper nanoclusters through the use of hydrogen peroxide additive and their application for the fluorescence detection of Hg2+ in water samples?
  Liao Xiaoqing,Li Ruiyi,Li Zaijun,Sun Xiulan,Wang Zhouping,Liu Junkang New J. Chem., 2015,39, 5240-5248
• 3. Estimates of hydride ion stability in condensed systems: energy of formation and solvation in aqueous and polar-organic solvents
  Craig A. Kelly,David R. Rosseinsky Phys. Chem. Chem. Phys., 2001,3, 2086-2090
• 4. Establishment and implications of a characterization method for magnetic nanoparticle using cell tracking velocimetry and magnetic susceptibility modified solutions
  Huading Zhang,Lee R. Moore,Maciej Zborowski,P. Stephen Williams,Shlomo Margel,Jeffrey J. Chalmers Analyst, 2005,130, 514-527
• 5. Examination of deposit in commercial diluted phosphoric acid
  Analyst, 1880,5, 146-147

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Isocoumarans Phthalides
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Isocoumarans Isobenzofuranones Phthalides

Comprehensive Overview of Mycophenolic Acid Carboxybutoxy Ether (CAS No. 931407-27-1): Properties, Applications, and Research Insights

Mycophenolic Acid Carboxybutoxy Ether (CAS No. 931407-27-1) is a chemically modified derivative of mycophenolic acid, a well-known immunosuppressive agent. This compound has garnered significant attention in pharmaceutical research due to its potential applications in drug delivery systems and targeted therapies. The carboxybutoxy ether modification enhances the solubility and bioavailability of the parent compound, making it a promising candidate for advanced therapeutic formulations.

In recent years, the demand for Mycophenolic Acid Carboxybutoxy Ether has surged, driven by its role in the development of next-generation immunosuppressants. Researchers are particularly interested in its ability to modulate immune responses with reduced side effects compared to traditional therapies. This aligns with the growing trend of personalized medicine, where patients seek treatments tailored to their specific needs. The compound's unique chemical structure, characterized by the carboxybutoxy ether side chain, allows for precise control over drug release kinetics, a feature highly valued in modern pharmacology.

The synthesis of Mycophenolic Acid Carboxybutoxy Ether involves a series of carefully controlled reactions to ensure high purity and yield. Analytical techniques such as HPLC and NMR are routinely employed to verify the compound's identity and quality. These methods are critical for meeting regulatory standards, especially in the pharmaceutical industry where consistency and safety are paramount. The CAS No. 931407-27-1 serves as a unique identifier, facilitating accurate documentation and traceability in research and commercial applications.

One of the most frequently asked questions about Mycophenolic Acid Carboxybutoxy Ether pertains to its mechanism of action. Studies suggest that it inhibits inosine monophosphate dehydrogenase (IMPDH), an enzyme essential for purine synthesis in lymphocytes. This selective inhibition makes it a valuable tool for managing autoimmune diseases and preventing organ transplant rejection. The compound's carboxybutoxy ether moiety further enhances its pharmacokinetic profile, ensuring sustained therapeutic effects with minimal toxicity.

Another area of interest is the compound's potential in combination therapies. With the rise of multidrug-resistant pathogens and complex chronic conditions, researchers are exploring synergistic effects between Mycophenolic Acid Carboxybutoxy Ether and other bioactive molecules. Such combinations could revolutionize treatment protocols, offering improved efficacy and patient outcomes. This aligns with the broader healthcare trend of integrating multiple therapeutic modalities to address multifaceted diseases.

From an industrial perspective, the scalability of Mycophenolic Acid Carboxybutoxy Ether production is a key consideration. Advances in green chemistry and continuous flow synthesis have enabled more efficient and environmentally friendly manufacturing processes. These innovations not only reduce production costs but also minimize waste, contributing to sustainable pharmaceutical development. The compound's CAS No. 931407-27-1 is often referenced in patents and technical literature, underscoring its commercial and scientific significance.

In conclusion, Mycophenolic Acid Carboxybutoxy Ether (CAS No. 931407-27-1) represents a cutting-edge advancement in medicinal chemistry. Its unique properties, coupled with its potential for diverse applications, make it a focal point of contemporary research. As the healthcare landscape continues to evolve, this compound is poised to play a pivotal role in shaping the future of immunotherapy and precision medicine. Researchers and industry professionals alike are encouraged to explore its full potential, leveraging its carboxybutoxy ether functionality to develop innovative solutions for unmet medical needs.

• 31858-65-8(O-Desmethyl Mycophenolic Acid)
• 31858-66-9(Methyl mycophenolate)
• 24280-93-1(Mycophenolic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)